Case Report
BibTex RIS Cite

Development of AA Amyloidosis in a Patient with Psoriasis: A Case Report

Year 2022, Volume: 4 - Supplement 1, 178 - 181, 01.04.2022
https://doi.org/10.46310/tjim.1072829

Abstract

Psoriasis is a chronic, recurrent, inflammatory and common skin disease of unknown aetiology. Amyloidosis is defined as a heterogeneous group of diseases in which generally soluble plasma proteins accumulate in the extracellular space as insoluble abnormal fibrils. Type AA amyloidosis is a late and severe complication of chronic inflammatory disorders and some chronic infections. Although psoriasis is a common inflammatory skin disease, the development of amyloidosis is rare. Herein, we presented a case of psoriasis who developed AA-type amyloidosis.

References

  • Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002 Feb;440(2):111-22. doi: 10.1007/s00428-001-0582-9.
  • Mansur AT, Akbayır N, Gündüz S, Peker Ö. Gastrointestinal amyloidosis in a patient with generalized pustular and arthropathic psoriasis. Turkderm-Turk Arch Dermatol Venereol. 2006;40(B):60-3 (in Turkish).
  • Kagana A, Husza’r M, Frumkinc A, Rapoporta J. Reversal of nephrotic syndrome due to aa amyloidosis in psoriatic patients onlong-term colchicine treatment: Case report and review of the literature. Nephron 1999;82:348-53. doi: 10.1159/000045450.
  • Wittenberg GP, Oursler JR, Peters MS. Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol. 1995 Mar;32(3):465- 8. doi: 10.1016/0190-9622(95)90070-5.
  • Karakoç Y, Dalkılıç E, Güllülü M, Yavuz M, Ersoy A, Yurtkuran M. Renal amyloidosis in rheumatic diseases. Office Journal of the Turkish Nephrology Association. 1999;3:143-6 (in Turkish).
  • Akar S, Solmaz D. The reflection of disease progression in axial spondylarthritis to the imaging.Ulus Romatol Derg. 2020;12(Suppl 2):54-66. doi: 10.4274/raed.galenos.2020.S108.
  • Cansu SÜ, Korkmaz C. Psoriatic arthritis treatment: 2015 Update. Osmangazi Journal of Medicine, 2016;38(1):17.25 (in Turkish). doi: 10.20515/otd.91313.
  • Aytuğar E, Pekiner FM. Behçet hastalığı. Journal of Marmara University Institute of Health Sciences. 2011;1(1):65-73 (in Turkish).
  • Mérida E, Praga M. NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1280-2. doi: 10.2215/ CJN.08090719.
  • Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006 Apr;6(2):214-20. doi: 10.1016/j. coph.2005.10.005.
Year 2022, Volume: 4 - Supplement 1, 178 - 181, 01.04.2022
https://doi.org/10.46310/tjim.1072829

Abstract

References

  • Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002 Feb;440(2):111-22. doi: 10.1007/s00428-001-0582-9.
  • Mansur AT, Akbayır N, Gündüz S, Peker Ö. Gastrointestinal amyloidosis in a patient with generalized pustular and arthropathic psoriasis. Turkderm-Turk Arch Dermatol Venereol. 2006;40(B):60-3 (in Turkish).
  • Kagana A, Husza’r M, Frumkinc A, Rapoporta J. Reversal of nephrotic syndrome due to aa amyloidosis in psoriatic patients onlong-term colchicine treatment: Case report and review of the literature. Nephron 1999;82:348-53. doi: 10.1159/000045450.
  • Wittenberg GP, Oursler JR, Peters MS. Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol. 1995 Mar;32(3):465- 8. doi: 10.1016/0190-9622(95)90070-5.
  • Karakoç Y, Dalkılıç E, Güllülü M, Yavuz M, Ersoy A, Yurtkuran M. Renal amyloidosis in rheumatic diseases. Office Journal of the Turkish Nephrology Association. 1999;3:143-6 (in Turkish).
  • Akar S, Solmaz D. The reflection of disease progression in axial spondylarthritis to the imaging.Ulus Romatol Derg. 2020;12(Suppl 2):54-66. doi: 10.4274/raed.galenos.2020.S108.
  • Cansu SÜ, Korkmaz C. Psoriatic arthritis treatment: 2015 Update. Osmangazi Journal of Medicine, 2016;38(1):17.25 (in Turkish). doi: 10.20515/otd.91313.
  • Aytuğar E, Pekiner FM. Behçet hastalığı. Journal of Marmara University Institute of Health Sciences. 2011;1(1):65-73 (in Turkish).
  • Mérida E, Praga M. NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1280-2. doi: 10.2215/ CJN.08090719.
  • Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006 Apr;6(2):214-20. doi: 10.1016/j. coph.2005.10.005.
There are 10 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Case Reports
Authors

Mehmet Sezen 0000-0001-5796-6445

Müge Şahin 0000-0002-7348-2771

Abdülmecit Yıldız 0000-0001-5941-9103

Ayşegül Oruç 0000-0002-0342-9692

Saide Güllülü 0000-0001-6048-1879

Mahmut Yavuz 0000-0001-6755-6386

Mustafa Güllülü 0000-0002-8911-7189

Kamil Dilek 0000-0001-6149-1913

Alparslan Ersoy 0000-0002-0710-0923

Publication Date April 1, 2022
Submission Date February 13, 2022
Acceptance Date March 9, 2022
Published in Issue Year 2022 Volume: 4 - Supplement 1

Cite

EndNote Sezen M, Şahin M, Yıldız A, Oruç A, Güllülü S, Yavuz M, Güllülü M, Dilek K, Ersoy A (April 1, 2022) Development of AA Amyloidosis in a Patient with Psoriasis: A Case Report. Turkish Journal of Internal Medicine 4 178–181.

e-ISSN: 2687-4245 

Turkish Journal of Internal Medicine, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png
2024 -TJIM.org